Publications

Taylor SR.  2021.  Dietary fructose improves intestinal cell survival and nutrient absorption.. Nature. 597:263-267.

McElvaine AT, Hawkins-Salsbury JA, Arora VM, Gladwin MT, Goldenring JR, Huston DP, Krakow D, Rhee K, Solway J, Steinman RA et al..  2021.  Innovations in MD-only physician-scientist training: experiences from the Burroughs Wellcome Fund physician-scientist institutional award initiative.. J Clin Invest. 131(10)

Planck KA, Rhee K.  2021.  Metabolomics of Mycobacterium tuberculosis.. Methods Mol Biol. 2314:579-593.

Aldridge BB, Barros-Aguirre D, Barry CE, Bates RH, Berthel SJ, Boshoff HI, Chibale K, Chu X-J, Cooper CB, Dartois V et al..  2021.  The Tuberculosis Drug Accelerator at year 10: what have we learned? Nat Med. 27(8):1333-1337.

Ginn J, Jiang X, Sun S, Michino M, Huggins DJ, Mbambo Z, Jansen R, Rhee KY, Arango N, Lima CD et al..  2021.  Whole Cell Active Inhibitors of Mycobacterial Lipoamide Dehydrogenase Afford Selectivity over the Human Enzyme through Tight Binding Interactions.. ACS Infect Dis. 7(2):435-444.

Szeri F, Lundkvist S, Donnelly S, Engelke UFH, Rhee K, Williams CJ, Sundberg JP, Wevers RA, Tomlinson RE, Jansen RS et al..  2020.  The membrane protein ANKH is crucial for bone mechanical performance by mediating cellular export of citrate and ATP.. PLoS Genet. 16(7):e1008884.

Hards K, Adolph C, Harold LK, McNeil MB, Cheung C-Y, Jinich A, Rhee KY, Cook GM.  2020.  Two for the price of one: Attacking the energetic-metabolic hub of mycobacteria to produce new chemotherapeutic agents.. Prog Biophys Mol Biol. 152:35-44.

Xia Q, Lee MHee, Walsh KF, McAulay K, Bean JM, Fitzgerald DW, Dupnik KM, Johnson WD, Pape JW, Rhee KY et al..  2020.  Urinary biomarkers of mycobacterial load and treatment response in pulmonary tuberculosis.. JCI Insight. 5(18)

Isa F, Collins S, Lee MHee, Decome D, Dorvil N, Joseph P, Smith L, Salerno S, Wells MT, Fischer S et al..  2018.  Mass Spectrometric Identification of Urinary Biomarkers of Pulmonary Tuberculosis.. EBioMedicine. 31:157-165.

Ehrt, Sabine, Schnappinger D, Rhee KY.  2018.  Metabolic principles of persistence and pathogenicity in Mycobacterium tuberculosis.. Nat Rev Microbiol. 16(8):496-507.

Chen C, Gardete S, Jansen RSander, Shetty A, Dick T, Rhee KY, Dartois V.  2018.  Verapamil Targets Membrane Energetics in Mycobacterium tuberculosis.. Antimicrob Agents Chemother. 62(5)

Jansen RS, Rhee KY.  2017.  Emerging Approaches to Tuberculosis Drug Development: At Home in the Metabolome.. Trends Pharmacol Sci. 38(4):393-405.

Park Y, Pacitto A, Bayliss T, Cleghorn LAT, Wang Z, Hartman T, Arora K, Ioerger TR, Sacchettini J, Rizzi M et al..  2017.  Essential but Not Vulnerable: Indazole Sulfonamides Targeting Inosine Monophosphate Dehydrogenase as Potential Leads against Mycobacterium tuberculosis.. ACS Infect Dis. 3(1):18-33.

Hartman TE, Wang Z, Jansen RS, Gardete S, Rhee KY.  2017.  Metabolic Perspectives on Persistence.. Microbiol Spectr. 5(1)

Kardon JR, Yien YY, Huston NC, Branco DS, Hildick-Smith GJ, Rhee KY, Paw BH, Baker TA.  2015.  Mitochondrial ClpX Activates a Key Enzyme for Heme Biosynthesis and Erythropoiesis.. Cell. 161(4):858-67.

Ehrt, Sabine, Rhee K, Schnappinger D.  2015.  Mycobacterial genes essential for the pathogen's survival in the host.. Immunol Rev. 264(1):319-26.

Chakraborty S, Rhee KY.  2015.  Tuberculosis Drug Development: History and Evolution of the Mechanism-Based Paradigm.. Cold Spring Harb Perspect Med. 5(8):a021147.

Nixon MR, Saionz KW, Koo M-S, Szymonifka MJ, Jung H, Roberts JP, Nandakumar M, Kumar A, Liao R, Rustad T et al..  2014.  Folate pathway disruption leads to critical disruption of methionine derivatives in Mycobacterium tuberculosis.. Chem Biol. 21(7):819-30.

Baughn AD, Rhee KY.  2014.  Metabolomics of Central Carbon Metabolism in Mycobacterium tuberculosis.. Microbiol Spectr. 2(3)

Patel SJ, Oliveira AP, Zhou JJulia, Alba L, E Furuya Y, Weisenberg SA, Jia H, Clock SA, Kubin CJ, Jenkins SG et al..  2014.  Risk factors and outcomes of infections caused by extremely drug-resistant gram-negative bacilli in patients hospitalized in intensive care units.. Am J Infect Control. 42(6):626-31.

Zhou JJulia, Patel SJ, Jia H, Weisenberg SA, E Furuya Y, Kubin CJ, Alba L, Rhee K, Saiman L.  2013.  Clinicians' knowledge, attitudes, and practices regarding infections with multidrug-resistant gram-negative bacilli in intensive care units.. Infect Control Hosp Epidemiol. 34(3):274-83.

Ehrt, Sabine, Rhee K.  2013.  Mycobacterium tuberculosis metabolism and host interaction: mysteries and paradoxes.. Curr Top Microbiol Immunol. 374:163-88.

Weisenberg SA, Mediavilla JR, Chen L, Alexander EL, Rhee KY, Kreiswirth BN, Jenkins SG.  2012.  Extended spectrum beta-lactamase-producing Enterobacteriaceae in international travelers and non-travelers in New York City.. PLoS One. 7(9):e45141.

Lakshmanan V, Rhee KY, Wang W, Yu Y, Khafizov K, Fiser A, Wu P, Ndir O, Mboup S, Ndiaye D et al..  2012.  Metabolomic analysis of patient plasma yields evidence of plant-like α-linolenic acid metabolism in Plasmodium falciparum.. J Infect Dis. 206(2):238-48.

de Carvalho LPedro S, Ling Y, Shen C, J Warren D, Rhee KY.  2011.  On the chemical mechanism of succinic semialdehyde dehydrogenase (GabD1) from Mycobacterium tuberculosis.. Arch Biochem Biophys. 509(1):90-9.